Please assess the completion status of the following clinical trial:

Trial Title: EScitalopram PIndolol ONset of Action

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged between 18 and 65 years old~* patients suffering from major depression according to DSM-IV with a MADRS score of at least 25 and not treated by an antidepressant at the time of inclusion with the exception of non-responders to antidepressant for a period of at least 6 weeks or not tolerating an ongoing antidepressant necessitating a change of the antidepressant(excluding fluoxetine and irreversible MAOI)~* informed consent~Exclusion criteria:~* any other Axis I disorder excluding anxiety disorder not dominating the clinical picture, nicotine abuse~* non-responders to escitalopram in the past~* already taking pindolol~* pregnancy and breast feeding~* contraindication to one of the two treatments (medical conditions, drug treatments)~* significant somatic comorbidity interfering with the study procedures~* high risk of suicidality~* women of childbearing age not having a safe means of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- escitalopram 20mg + pindolol 15mg (Type: EXPERIMENTAL): Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
- Escitalopram 30 mg (Type: ACTIVE_COMPARATOR): Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
- escitalopram 20 mg (Type: ACTIVE_COMPARATOR): days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).